Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab

Patients with refractory or relapsed (R/R) acute lymphoblastic leukemia (ALL) have a dismal prognosis of around 5% long-term survival when treated with cytotoxic chemotherapy and allogenic stem cell transplantation. T-cell immunobased strategies open up new therapeutic perspectives. Blinatumomab is...

Descripción completa

Detalles Bibliográficos
Autores principales: Queudeville, Manon, Handgretinger, Rupert, Ebinger, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530848/
https://www.ncbi.nlm.nih.gov/pubmed/28790849
http://dx.doi.org/10.2147/OTT.S103470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530848/
https://www.ncbi.nlm.nih.gov/pubmed/28790849
http://dx.doi.org/10.2147/OTT.S103470

Ejemplares similares